Crossmark

Pharmacodynamic and pharmacokinetic properties of the combined preparation of levothyroxine plus sustained- release liothyronine; a randomized controlled clinical trial

Crossref DOI link: https://doi.org/10.1186/s12902-023-01434-y

Published Online: 2023-08-28

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mehran, Ladan

Amouzegar, Atieh

Foroutan, Seyed Mohsen

Masoumi, Safdar

Tohidi, Maryam

Abdi, Hengameh

Aghaei, Ali

Saghafinia, Amir Esmaeel

Azizi, Fereidoun
License Information

Text and Data Mining valid from 2023-08-28

Version of Record valid from 2023-08-28
More Information

Article History

Received: 26 December 2022

Accepted: 16 August 2023

First Online: 28 August 2023

Declarations

:

: This study was conducted in concordance with the Helsinki Declaration ethical principles, and all procedures on the study participants were approved by the National Research Council of the Islamic Republic of Iran (IR.SBMU.ENDOCRINE.REC.1400.031), the Human Research Review Committee of the Endocrine Research Center, Shahid Beheshti University, Tehran, Iran. Trial participants signed informed consent forms at baseline, and their personal information would remain strictly confidential.

: “Not applicable”.

: On behalf of all authors, the corresponding author states that there is no conflict of interest.

Document is current

Any future updates will be listed below